<DOC>
	<DOCNO>NCT00777582</DOCNO>
	<brief_summary>The purpose phase I randomise cross study determine compare bioavailability two different oral formulation AZD2281 advance solid tumour cancer patient</brief_summary>
	<brief_title>Phase I Comparative Bioavailability Study</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<criteria>Histologically confirm malignant advance solid tumour , refractory standard therapy ( except Group 8 patient must platinum refractory ) suitable effective standard therapy exist Patients must adequate organ bone marrow function measure within 7 day prior administration study treatment Female patient must evidence nonchild bear status : negative urine serum pregnancy test within 7 day study treatment woman child bearing , postmenopausal status Patients receive chemotherapy , radiotherapy ( except palliative reason ) anticancer therapy within 4 week last dose prior study entry . Patients may continue use biphosphonates bone metastasis corticosteroid Patients symptomatic uncontrolled brain metastasis Major surgery within 2 week start study patient must recover effect major surgery Patients platinum refractory ( Group 8 ) Patients myelodysplastic syndrome/acute myeloid leukaemia ( Group 8 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
	<keyword>Homologous Recombination Deficiency ( HRD )</keyword>
	<keyword>Advanced solid tumour</keyword>
</DOC>